Role of early assessment of antiangiogenic treatment in metastatic colorectal cancer using quantitative contrast-enhanced ultrasonography
10.3760/cma.j.issn.1004-4477.2016.06.012
- VernacularTitle:超声造影定量分析在晚期结直肠癌患者抗血管治疗早期疗效评估中的作用
- Author:
Chen YANG
;
Liming ZHU
;
Chanjuan PENG
;
Liyu CHEN
;
Liping WANG
;
Na FENG
;
Weiyun PAN
- Publication Type:Journal Article
- Keywords:
Contrast-enhanced ultrasonography;
Colorectal neoplasms;
Bevacizumab;
Response evaluation
- From:
Chinese Journal of Ultrasonography
2016;25(6):510-515
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the application of contrast-enhanced ultrasonograhy CEUS in the early assessment of antiangiogenic treatment in metastatic colorectal cancer Methods Among 41 colorectal cancer patients with liver metastases enrolled in this study 25 patients received treatment of antiangiogenic treatment bevacizumab combined with chemotherapy BV group and 16 patients received chemotherapy only non-BV group To assess the treatment responses in the liver lesions between and within these two groups CEUS scans were performed before the treatment T0 or??baseline on the day 2 T1 and on the day 7 T2 after the treatment The percentage differences were evaluated according to the CEUS quantitative parameters such as rise time RT peak intensity PI mean transit time MTT area under the curve AUC time from peak to one half TPH wash in slope WIS and time to peak TTP Results On T1 both the RT and MTT increased within the BV group and decrease within the non-BV group when compared with their own baselines the differences were statistically significant P <0 05 On T2 the MTT increased within the BV group and decreased within the non-BV group when compared with their baselines the differences again were statistically significant P <0 05 All other parameters measured on T1 and T2 did not show a significant difference when compared with baselines Within the BV group the RT decreased and WIS and TPH increased for the responding subjects when compared with the non-responding subjects the differences were statistically significant P < 0 05 Within the non-BV group however no statistically significant differences were found for all parameters between the responding subjects and non-responding subjects P >0 05 Conclusions CEUS can be used to assess the treatment response in liver metastatic patients with colorectal cancer by monitoring the change of the tumor perfusion before and after the treatment.
